It is worth noting that the intratumoral heterogeneity and dynamic nature of PD-L1 expression across the tumor-tissue could influence the reliability of PD-L1 as a predicative biomarker for the response to anti-PD-1/PD-L1 immunotherapy (184). The gene discussed is CD274; the disease is neoplasm.